Midostaurin for Patients With Acute Myeloid Leukemia and FLT3 Mutations  

Mark James Levis, MD, PhD

  H&O  What is the role of FLT3 in normal cells and acute myeloid leukemia? ML  FLT3 is a receptor tyrosine kinase. The name stands for […]

From Recent Issues

Immunotherapy in Colorectal Cancer With Mismatch Repair Deficiency

  H&O  Which immunotherapy agents have been approved for use in colorectal cancer (CRC) with mismatch repair deficiency (MMR-D)? MO  We have a choice of 3 […]

The Evolving Understanding of Prognosis in Post–Essential Thrombocythemia Myelofibrosis and Post–Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis

  Abstract: Myelofibrosis (MF) is the most aggressive of the classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). In some patients with essential thrombocytopenia or polycythemia vera, which […]

Does FCR Have the Potential to Cure a Subgroup of Patients With Chronic Lymphocytic Leukemia?

  H&O  When is first-line treatment initiated in patients with CLL? WW  In chronic lymphocytic leukemia (CLL), patients should meet a standard criteria to initiate treatment. […]

Supplements

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting

A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California 2-Year Follow-Up and High-Risk […]

A Clinician’s Perspective of Treatment of Relapsed or Refractory Multiple Myeloma

Click the “Download PDF” button to read Dr. Paul G. Richardson’s perspective on treatment of relapsed or refractory multiple myeloma.      

Highlights in Advanced Prostate Cancer From the 2019 ASCO Genitourinary Cancers Symposium

A Review of Selected Presentations From the 2019 ASCO Genitourinary Cancers Symposium • February 14-16, 2019 • San Francisco, California   ARAMIS: Efficacy and Safety of […]